• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于血清蛋白生物标志物的结直肠癌和高级腺瘤筛查，我们的现状如何？系统评价。

Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review.

机构信息

U1086 "ANTICIPE" INSERM-University of Caen Normandy, Centre François Baclesse, Caen, France.

Department of Hepato-Gastroenterology and Digestive Oncology, Rouen University Hospital, France.

出版信息

Mol Oncol. 2024 Nov;18(11):2629-2648. doi: 10.1002/1878-0261.13734. Epub 2024 Sep 30.

DOI:10.1002/1878-0261.13734
PMID:39344882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11547240/
Abstract

Colorectal cancer (CRC) screening has been proven to reduce both mortality and the incidence of this disease. Most CRC screening programs are based on fecal immunochemical tests (FITs), which have a low participation rate. Searching for blood protein biomarkers can lead to the development of a more accepted screening test. The aim of this systematic review was to compare the diagnostic potential of the most promising serum protein biomarkers. A systematic review based on PRISMA guidelines was conducted in the PubMed and Web of Science databases between January 2010 and December 2023. Studies assessing blood protein biomarkers for CRC screening were included. The sensitivity, specificity, and area under the ROC curve of each biomarker were collected. Among 4685 screened studies, 94 were considered for analysis. Most of them were case-control studies, leading to an overestimation of the performance of candidate biomarkers. The performance of no protein biomarker or combination of biomarkers appears to match that of the FIT. Studies with a suitable design and population, testing new assay techniques, or based on algorithms combining FIT with serum tests are needed.

摘要

结直肠癌（CRC）筛查已被证明可降低死亡率和疾病发生率。大多数 CRC 筛查计划基于粪便免疫化学检测（FITs），但参与率较低。寻找血液蛋白生物标志物可开发出更易被接受的筛查检测方法。本系统评价旨在比较最有前途的血清蛋白生物标志物的诊断潜力。根据 PRISMA 指南，在 PubMed 和 Web of Science 数据库中对 2010 年 1 月至 2023 年 12 月期间发表的研究进行了系统评价。纳入评估血液蛋白生物标志物用于 CRC 筛查的研究。收集了每个生物标志物的敏感性、特异性和 ROC 曲线下面积。在筛选出的 4685 项研究中，有 94 项被认为适合分析。其中大多数是病例对照研究，这导致候选生物标志物的性能被高估。没有一种蛋白生物标志物或标志物组合的性能似乎与 FIT 相匹配。需要进行设计和人群合适、测试新检测技术或基于结合 FIT 和血清检测的算法的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/562bfc9c04f8/MOL2-18-2629-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/de6aadd5474b/MOL2-18-2629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/39d003a34bf3/MOL2-18-2629-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/562bfc9c04f8/MOL2-18-2629-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/de6aadd5474b/MOL2-18-2629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/39d003a34bf3/MOL2-18-2629-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0546/11547240/562bfc9c04f8/MOL2-18-2629-g003.jpg

相似文献

1
Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review.基于血清蛋白生物标志物的结直肠癌和高级腺瘤筛查，我们的现状如何？系统评价。
Mol Oncol. 2024 Nov;18(11):2629-2648. doi: 10.1002/1878-0261.13734. Epub 2024 Sep 30.
2
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.基于愈创木脂的粪便潜血试验与粪便免疫化学试验用于一般风险人群结直肠癌筛查。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2.
3
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.粪便免疫化学检测用于在初级保健中对有下腹部症状的患者进行分流，以确定是否需要转诊疑似结直肠癌患者：一项系统评价和成本效益分析。
Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330.
4
Chemoprevention of colorectal cancer: systematic review and economic evaluation.结直肠癌的化学预防：系统评价和经济评估。
Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320.
5
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果：来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
6
Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people.老年人即将发生和当前失水脱水的识别的临床症状、体征及检查
Cochrane Database Syst Rev. 2015 Apr 30;2015(4):CD009647. doi: 10.1002/14651858.CD009647.pub2.
7
Cascade colorectal cancer screening guidelines: a global conceptual model.级联结直肠癌筛查指南：一个全球概念模型。
J Clin Gastroenterol. 2011 Apr;45(4):297-300. doi: 10.1097/MCG.0b013e3182098e07.
8
Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.用于结直肠癌筛查的粪便检测：从潜血试验到DNA分析
J Gastrointest Cancer. 2016 Jun;47(2):143-51. doi: 10.1007/s12029-016-9810-z.
9
First trimester serum tests for Down's syndrome screening.孕早期唐氏综合征筛查的血清学检测
Cochrane Database Syst Rev. 2015 Nov 30;2015(11):CD011975. doi: 10.1002/14651858.CD011975.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中，如果患者出现以下症状和体征，可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

本文引用的文献

1
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.基于无细胞游离 DNA 的血液检测用于结直肠癌筛查。
N Engl J Med. 2024 Mar 14;390(11):973-983. doi: 10.1056/NEJMoa2304714.
2
Blood Biomarkers Panels for Screening of Colorectal Cancer and Adenoma on a Machine Learning-Assisted Detection Platform.基于机器学习辅助检测平台的用于结直肠癌和腺瘤筛查的血液生物标志物检测面板。
Cancer Control. 2023 Jan-Dec;30:10732748231222109. doi: 10.1177/10732748231222109.
3
Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer.
白细胞免疫球蛋白样受体 B2 过表达作为结直肠癌有前途的治疗靶点和非侵入性筛查生物标志物。
World J Gastroenterol. 2023 Oct 7;29(37):5313-5326. doi: 10.3748/wjg.v29.i37.5313.
4
Early Screening of Colorectal Precancerous Lesions Based on Combined Measurement of Multiple Serum Tumor Markers Using Artificial Neural Network Analysis.基于人工神经网络分析的多种血清肿瘤标志物联合检测对结直肠癌前病变的早期筛查
Biosensors (Basel). 2023 Jun 27;13(7):685. doi: 10.3390/bios13070685.
5
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.一种评估结直肠癌新型无创筛查检测的有效策略：指导原则。
Gut. 2023 Oct;72(10):1904-1918. doi: 10.1136/gutjnl-2023-329701. Epub 2023 Jul 18.
6
Exploring non-participation in colorectal cancer screening: A systematic review of qualitative studies.探索结直肠癌筛查不参与情况：定性研究的系统综述。
Soc Sci Med. 2023 Jul;329:116022. doi: 10.1016/j.socscimed.2023.116022. Epub 2023 Jun 13.
7
The Diagnosis Significance of Serum Cysteine Protease Inhibitors (CST4) in Colorectal Cancer.血清半胱氨酸蛋白酶抑制剂（CST4）在结直肠癌中的诊断意义。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231164232. doi: 10.1177/15330338231164232.
8
p53 and p63 Proteoforms Derived from Alternative Splicing Possess Differential Seroreactivity in Colorectal Cancer with Distinct Diagnostic Ability from the Canonical Proteins.源自可变剪接的p53和p63蛋白异构体在结直肠癌中具有不同的血清反应性，与经典蛋白相比具有独特的诊断能力。
Cancers (Basel). 2023 Mar 31;15(7):2102. doi: 10.3390/cancers15072102.
9
Blood Test Increases Colorectal Cancer Screening in Persons Who Declined Colonoscopy and Fecal Immunochemical Test: A Randomized Controlled Trial.血液检测增加拒绝结肠镜检查和粪便免疫化学试验者的结直肠癌筛查：一项随机对照试验。
Clin Gastroenterol Hepatol. 2023 Oct;21(11):2951-2957.e2. doi: 10.1016/j.cgh.2023.03.036. Epub 2023 Apr 8.
10
Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.优化结直肠癌筛查：一种结合粪便免疫化学检测、血液癌症相关蛋白和人口统计学信息以降低结肠镜检查负担的算法。
Clin Colorectal Cancer. 2023 Jun;22(2):199-210. doi: 10.1016/j.clcc.2023.02.001. Epub 2023 Feb 15.